Effects of expression of ERCC1, RRM1 on survival trend of lung cancer with cisplatin combine gemcitabine chemotherapy after surgical resection

Chinese Journal of Lung Cancer

Volumn 12, Issue 5, 2009, Pages 403-407

  Liang, Weijun ^a   Hu, Chengping ^a   Gu, Qihua ^a   Song, Min ^a   Luo, Wanjun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cisplatin gemcitabine; Excision repair cross complementing gene 1; Lung neoplasms; Ribonucleotide reductase subunit 1

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 67449100056     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.05.005     Document Type: Article

References (12)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 2004, 350(4): 351-360.
2. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B-III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
3. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355(10): 983-991. (Pubitemid 44343542)
4. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res, 2000, 20(2A): 645-652. (Pubitemid 30240614)
5. Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer, 2008, 59(3): 377-384. (Pubitemid 351335101)
6. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 2005, 127(3): 978-983. (Pubitemid 40775532)
7. Yuan P, Miao XP, Zhang XM, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Ai Zheng, 2005, 24(12): 1510-1513.
8. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 2007, 56(2): 281-288. (Pubitemid 46590484)
9. Smith BD, Judith E. Ribonucleotide reductase: an old target with new potential. Leukemia Research, 2003, 27(12): 1075-1076. (Pubitemid 36960025)
10. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17(12): 1818-1825. (Pubitemid 44884058)
11. Rosell R, Danenberg KD, Alberoija V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10(4): 1318-1325. (Pubitemid 38365223)
12. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res, 2004, 10(12 Pt 2): 4215s-4219s. (Pubitemid 38812449)